Hugel Inc (145020 KS): Achieves Record High Revenue and Operating Profit in 4Q23
Hugel has received FDA approval for its botulinum toxin Letybo and becomes the only Korean company and one of the top 3 players globally that have...
749 Views
Hugel Inc (145020 KS): Record High Performance in 2024; Continued Global Expansion to Drive Growth
Hugel achieves record sales and profits in 2024, driven by strong performance across all segments. US launch of toxin is expected in 1H25. Hugel...
712 Views
2023 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe
Despite ongoing recovery and fading effect of the COVID-19, healthcare companies had varying performances in 2023. From my coverage, the top...
762 Views
APAC Healthcare Weekly (November 2) – Takeda, Eisai, Wuxi AppTec, Celltrion, CSL, PharmaEssentia
Takeda and Eisai witnessed clinical trials setback. Wuxi AppTec is selling China-based CRO subsidiaries. CSL is delaying demerger of CSL Seqirus....
746 Views
APAC Healthcare Weekly (October 19) – Hansoh, Leads Biolabs, Chugai, SanBio, Celltrion, Samsung Bio
Hansoh and Leads Biolabs bag global outlicensing deals. Chugai’s partner Lilly announced positive P3 result for orforglipron. Celltrion launched...
878 Views